These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31843964)

  • 1. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Not Induced in Artificial Human Inflammation and Is Not Correlated with Inflammatory Response.
    Heinzl MW; Resl M; Klammer C; Egger M; Dieplinger B; Clodi M
    Infect Immun; 2020 Feb; 88(3):. PubMed ID: 31843964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
    Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
    Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of lipoproteins and proprotein convertase subtilisin/kexin type 9 in endotoxin clearance in sepsis.
    Walley KR
    Curr Opin Crit Care; 2016 Oct; 22(5):464-9. PubMed ID: 27552305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
    Reyes-Soffer G; Pavlyha M; Ngai C; Thomas T; Holleran S; Ramakrishnan R; Karmally W; Nandakumar R; Fontanez N; Obunike J; Marcovina SM; Lichtenstein AH; Matthan NR; Matta J; Maroccia M; Becue F; Poitiers F; Swanson B; Cowan L; Sasiela WJ; Surks HK; Ginsberg HN
    Circulation; 2017 Jan; 135(4):352-362. PubMed ID: 27986651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
    Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
    Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions.
    Hilvo M; Simolin H; Metso J; Ruuth M; Öörni K; Jauhiainen M; Laaksonen R; Baruch A
    Atherosclerosis; 2018 Feb; 269():159-165. PubMed ID: 29366988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
    Filippatos TD; Kei A; Rizos CV; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
    Dijk W; Le May C; Cariou B
    Trends Endocrinol Metab; 2018 Jun; 29(6):420-434. PubMed ID: 29665987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters.
    Bianconi V; Schiaroli E; Pirro M; Cardaci S; Busti C; Mannarino MR; Baldelli F; Francisci D
    HIV Med; 2020 Sep; 21(8):512-522. PubMed ID: 32496664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
    Kwakernaak AJ; Lambert G; Slagman MC; Waanders F; Laverman GD; Petrides F; Dikkeschei BD; Navis G; Dullaart RP
    Atherosclerosis; 2013 Feb; 226(2):459-65. PubMed ID: 23261172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.
    Ferri N; Corsini A; Macchi C; Magni P; Ruscica M
    Transl Res; 2016 Jul; 173():19-29. PubMed ID: 26548330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
    Bojanin D; Vekic J; Milenkovic T; Vukovic R; Zeljkovic A; Stefanovic A; Janac J; Ivanisevic J; Mitrovic K; Miljkovic M; Spasojevic-Kalimanovska V
    Atherosclerosis; 2019 Jan; 280():14-20. PubMed ID: 30453116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.
    Baragetti A; Grejtakova D; Casula M; Olmastroni E; Jotti GS; Norata GD; Catapano AL; Bellosta S
    Pharmacol Res; 2018 Apr; 130():1-11. PubMed ID: 29428206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease.
    Nozue T; Hattori H; Ogawa K; Kujiraoka T; Iwasaki T; Hirano T; Michishita I
    Lipids Health Dis; 2016 Sep; 15(1):165. PubMed ID: 27658826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.